Cytotoxicity and ROS Production of Novel Pt(IV) Oxaliplatin Derivatives with Indole Propionic Acid

In this study we evaluated the cytotoxicity of Pt(IV) complexes based on the oxaliplatin scaffold and the pro-oxidant indole-3-propionate in cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. A series of five complexes was synthesized and characterized by 1H and 195Pt NMR spectroscopy, IR spectroscopy, mass spectrometry and elemental analysis; trans-[Pt(DACH)(ox)(IPA)(OH)] (1), trans-[Pt(DACH)(ox)(IPA)2] (2), trans-[Pt(DACH)(ox)(IPA)(bz)] (3), trans-[Pt(DACH)(ox)(IPA)(suc)] (4), and trans-[Pt(DACH)(ox)(IPA)(ac)] (5) (DACH = 1,2-diaminocyclohexane (1R,2R)-(−), ox = oxalate, IPA = indole-3-propionate, bz = benzoate, suc = succinate and ac = acetate). The complexes were shown to produce cellular reactive oxygen species (ROS) in a time-dependent manner. The most potent ROS producer, complex 1, also elicited the highest cytotoxicity. Complex 1 was shown to form the mono- and bis-adducts [Pt(DACH)(guanosine)(OH)]+ and [Pt(DACH)(guanosine)2]2+ in the presence of ascorbic acid, suggesting that on activation the released oxaliplatin will interact with DNA.Graphical abstract
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research

Related Links:

Publication date: Available online 25 May 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Elisabeth Reiser, Stefanie Aust, Veronika Seebacher, Alexander Reinthaller, Hannah von Mersi, Richard Schwameis, Stephan Polterauer, Christoph Grimm, Samir Helmy-BaderAbstractObjectiveGamma-glutamyltransferase (GGT) is involved in tumor development, progression and chemotherapy resistance. The present study evaluated GGT serum levels as a preoperative predictive marker for ovarian cancer in patients with adnexal mass.Study DesignPreoperative GGT serum levels of 2235 patients with adnexal m...
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
ConclusionAbove results indicated that AKBA might be a potential compound to reverse MDR in human ovarian cancer.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
AbstractPurpose of ReviewThe consequence of treatment for gynaecological cancers can cause sudden onset of intense menopausal symptoms, such as vasomotor symptoms, sexual dysfunction and emotional instability. Hormone replacement therapy (HRT) is often effective and can overcome these unpleasant and severe symptoms. However, data regarding its safety remains controversial. The big question therefore is whether HRT in gynaecological cancer survivors is possible. This is due to the fear of disease relapse. So, the purpose of this study was to review the evidence regarding cancer recurrence or death following use of HRT in su...
Source: Current Obstetrics and Gynecology Reports - Category: OBGYN Source Type: research
Gamma-glutamyltransferase (GGT) is involved in tumor development, progression and chemotherapy resistance. The present study evaluated GGT serum levels as a preoperative predictive marker for ovarian cancer in patients with adnexal mass.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Tags: Full length article Source Type: research
CONCLUSIONS: Our research emphasized the suppressor function of miR-655-3p in OC. By targeting RAB1A, miR-655-3p played a tumor suppressor role in OC. We affirmed the beneficial effects of miR-655-3p in OC cells for the first time, thus providing an experimental basis for the treatment of OC. PMID: 31114987 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: In this study, we revealed that DANCR could enhance the proliferation, migration and invasion capacities of ovarian cancer cells by upregulating IGF2. Our findings might offer a potential therapeutic choice for patients with ovarian cancer. PMID: 31114986 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
CONCLUSIONS: MiR-132 may regulate ovarian cancer's sensitivity to DDP and inhibit its invasion and metastasis by targeted regulation on Bmi-1. PMID: 31114988 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Contributors : Anna Witucka ; Karol Jopek ; Marcin Rucinski ; Krzysztof Ksi ążekSeries Type : Expression profiling by arrayOrganism :There is a paradigm that cancer cells are immortal, which indicates that they have an ability to bypass cellular senescence. This is often linked with an expression of telomerase which restores the telomeric DNA. Cellular senescence may be induced in cancer cells by their exposure to clinically relevant doses of ionizing radiation (radiotherapy) and chemotherapy. It means that even though cancer cells avoided senescence in the course of their immortalization, they preserved intact molecular...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Source Type: research
ConclusionsBack-to-back random-start ovarian stimulation may be an effective way to maximize fertility preservation, even in time-limited settings.
Source: Journal of Assisted Reproduction and Genetics - Category: Reproduction Medicine Source Type: research
AbstractPurposeTo compare the efficacy, safety, and tolerability profiles of pegylated liposomal doxorubicin and carboplatin (PLDC) with those of gemcitabine and carboplatin (GC) for the treatment of patients with platinum-sensitive recurrent ovarian cancer.MethodsOvarian cancer patients with recurrence  >  6 months after first-line platinum and taxane-based therapies were randomly assigned to PLDC [pegylated liposomal doxorubicin 30 mg/m2 plus carboplatin area under the curve (AUC) 5  mg/mL/min on day 1] every 4 weeks or GC (gemcitabine 1000 mg/m2 on days 1 and 8 plus carboplatin ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Eloxatin | Ovarian Cancer | Ovaries | Study | Vitamin C